Zhejiang Shengda Bio-Pharm Stock Forum

The company's low P/S ratio is due to its poor revenue performance. The industry's expected 45% growth next year contrasts with the company's declining revenue trend. If top-line growth doesn't improve, the P/S could drop further, possibly disappointing shareholders.

The company's low P/S ratio may be due to its lackluster revenue performance and the industry's projected growth of 35% in the next 12 months. Investors may feel that the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio.